반응 #1842584

반응 방정식

tert-butyl 4-(1-(8-(5,6-dimethoxypyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-yl)piperidine-3-carboxamido)benzoate

TFA

→

4-(1-(8-(5,6-dimethoxypyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-yl)piperidine-3-carboxamido)benzoic acid

수율 4.0%

용매

dichloromethane

반응 조건

후처리

1. 1
   농축The residue was concentrated in vacuo
2. 2
   기타The crude product was purified by prep-HPLC (Gemini 5u C18 150×21.2 mm
3. 3
   workup.WAITgradient conditions: 20% acetonitrile/80% water (0.1% TFA, v/v) initially, proceeding to 40% acetonitrile/60% water (0.1% TFA, v/v) in a linear fashion over 9 min

실험 절차

A mixture of tert-butyl 4-(1-(8-(5,6-dimethoxypyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-yl)piperidine-3-carboxamido)benzoate (150 mg, 0.26 mmol) and TFA (2 mL) in dichloromethane (2 mL) was stirred at room temperature for 2 h. The residue was concentrated in vacuo. The crude product was purified by prep-HPLC (Gemini 5u C18 150×21.2 mm; inject volume: 3 mL/inj, flow rate: 20 mL/min; wavelength: 214 nm and 254 nm; gradient conditions: 20% acetonitrile/80% water (0.1% TFA, v/v) initially, proceeding to 40% acetonitrile/60% water (0.1% TFA, v/v) in a linear fashion over 9 min) to give 4-(1-(8-(5,6-dimethoxypyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-yl)piperidine-3-carboxamido)benzoic acid (5 mg, 4%) as yellow solid. 1H NMR (300 MHz, DMSO): δ 10.36 (s, 1H), 10.25 (s, 1H), 8.14 (brs, 2H), 7.90-7.74 (m, 5H), 7.44 (s, 1H), 6.97 (s, 1H), 4.25-4.15 (m, 4 h), 3.91 (s, 3H), 3.77 (s, 3H), 2.67 (brs, 2H), 2.04-1.57 (m, 3H). LC-MS: [M+H]+, 517.9, tR=1.366 min, HPLC: 95.06% at 214 nm, 95.20% at 254 nm, tR=4.927 min.

출처